Drug Search Results
More Filters [+]

Duodopa

Alternative Names: duodopa, dm-1992, dm1992, dm 1992, ipx-066, ipx066, ipx 066, nd-0612, nd0612, nd 0612
Latest Update: 2024-02-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DDC Inhibitor,DR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Croatia | Cyprus | Czech | Denmark | Estonia | France | Germany | Hungary | India | Italy | Japan | Lithuania | New Zealand | Norway | Pakistan | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: NeuroDerm
Company Location: REHOVOT L3 7670203
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duodopa

Countries in Clinic: Austria, Belgium, Czech Republic, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2015-005814-31

P2

Active, not recruiting

Parkinson's Disease

2025-02-28

BouNDless

P3

Active, not recruiting

Parkinson's Disease

2023-05-18

BouNDless

P3

Active, not recruiting

Parkinson's Disease

2022-11-01

95%

BeyoND

P2

Active, not recruiting

Parkinson's Disease

2019-09-09

Recent News Events